NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.
As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.
Based in Strasbourg, France, Polyplus-transfection is a privately held biotech firm that develops solutions for the in vivo, in vitro, an ex vivo delivery of nucleic acids for research, bioproduction, and therapeutic applications.
Roche Glycart is a Swiss biotechnology firm owed by Roche.
Terms of the deal were not disclosed.